We used a high-throughput single agent and drug combination screening assay based on bright-field images to determine cell survival under treatment with auranofin (Aura), a clinically approved thioredoxin reductase inhibitor for rheumatoid arthritis, and the GSH synthesis blocker BSO (Figures 4B, C and Supplementary Figure 10). The gene discussed is PRDX5; the disease is rheumatoid arthritis.